The Dialysis-Related Amyloidosis Treatment Act of 2024 requires Medicare to cover and pay for treatments for dialysis-related amyloidosis, a serious condition that affects some long-term dialysis patients. The bill expands Medicare coverage to include any FDA-approved treatments for this condition when provided at dialysis facilities, along with any necessary supplies or services related to those treatments. This legislation affects Medicare beneficiaries with dialysis-related amyloidosis and dialysis facilities that provide these treatments. Medicare would pay 100 percent of reasonable charges for these treatments separately from regular dialysis services, rather than bundling them into existing dialysis payment rates. The bill takes effect immediately upon enactment and does not specify a dollar amount for funding, leaving costs to be determined by actual patient use and treatment expenses.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.